IDEXX Laboratories Inc. reported first‑quarter 2026 revenue of $1.141 billion, up 11% on an organic basis and 14% on a reported basis from the prior year. The increase was driven largely by a 15% rise in the Companion Animal Group, which generated $1.054 billion in revenue, and by a 20% reported growth in consumables sales. Diagnostics recurring revenue within the group grew 14% reported and 11% organic, underscoring the strength of the company’s subscription‑style model.
Diluted earnings per share reached $3.47, a $0.05 beat of the $3.42 consensus estimate and a 15% year‑over‑year increase from Q1 2025’s $2.96. Gross profit rose to $722.7 million, giving a 63.4% gross margin that improved by 90 basis points versus the prior year, while operating margin expanded by 100 basis points, reflecting effective cost control and pricing power.
Management raised its full‑year 2026 outlook, projecting revenue of $4.675 billion to $4.760 billion—an 8.6% to 10.6% increase over the previous range—and diluted EPS of $14.45 to $14.90, a 12% to 15% lift. The upgrade signals confidence in continued demand for InVue Dx and Cancer Dx platforms and the expansion of practice‑management software, as well as the resilience of recurring revenue streams.
CEO Jay Mazelsky said the company’s “excellent commercial execution delivered exceptional first‑quarter results and positions IDEXX for continued strength through 2026.” He added that the results were achieved “despite headwinds from clinical wellness visits, underscoring the durability of our growth model.” CFO Andrew Emerson noted that the quarter’s performance was driven by “continued execution in our companion animal business with benefits from IDEXX Innovations.”
Investors responded positively to the earnings beat and guidance raise, with analysts highlighting the company’s margin expansion and recurring revenue growth as key strengths. The market reaction reflected confidence in IDEXX’s pricing power and operational leverage amid a broader industry shift toward advanced diagnostics.
The results reinforce IDEXX’s moat in the veterinary diagnostics market and suggest that the company is well positioned to navigate macro headwinds such as declining U.S. clinical visits while continuing to capture market share from competitors. The raised guidance and strong quarterly performance provide a clear signal that IDEXX’s growth trajectory and margin resilience are likely to persist throughout 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.